Psychosomatics
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by BOWES, H. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BOWES, H. A.
Psychosomatics 5: 44-47, 1964
Copyright © 1964 Academy of Psychosomatic Medicine

Some Experiences with a Combination Of Amitriptyline and Perphenazine In Severe Psychiatric Syndromes

H. ANGUS BOWES M.D.1

1 Director of the Institute of Neurology and Psychological Medicine, 1600 University, Grand Forks, North Dakota

In a private psychiatric clinic with facilities in the wards of a general hospital, we have treated 100 patients suffering from severe and intractable psychiatric syndromes characterized by severe anxiety, depression and with obsessional and paranoid ideation. We used a combination of amitriptyline (Elavil) 40-200 mg. daily and perphenazine (Trilafon) 4-32 mg. daily, and have had a recovery rate of 71 per cent in a mean of five out-patient therapeutic sessions. In those cases requiring hospitalization plus modified E.S.T., the patients were given two to five treatments daily for a mean of five days' hospitalization and of 10 modified E.S.T. and then seen in three follow-up therapeutic sessions.

No double-blind studies have been carried out. The patients acted as their own controls since the majority had received antidepressant drugs and tranquilizers from their referring physicians. Those who did not make recoveries reached a plateau of improvement with a lack of drive and retention of hypochondriacal or phobic symptoms requiring respectively the additional administration of opipramol (Ensidon) 50 mg. q.i.d. or diazepam (Valium) 5-10 mg. q.i.d. before a further improvement was obtained. Only 7 per cent did not appear to benefit from the regimen; these were patients with poor personalities and lifelong maladaptation who appeared reluctant to abandon their secondary neurotic gains from their illness though their condition appeared improved not only to their families but also to the examining psychiatrists. The patients included in this study were chosen as a result of their profiles on the Minnesota Multiphasic Personality Inventory and our own clinical observations. Many included in this study appeared to be classical cases of schizophrenia.




This article has been cited by other articles:


Home page
Arch Gen PsychiatryHome page
S. G. Siris, D. P. van Kammen, and J. P. Docherty
Use of Antidepressant Drugs in Schizophrenia
Arch Gen Psychiatry, November 1, 1978; 35(11): 1368 - 1377.
[Abstract] [PDF]


Home page
Arch Gen PsychiatryHome page
G. Chouinard, L. Annable, M. Serrano, J. M. Albert, and R. Charette
Amitriptyline-Perphenazine Interaction in Ambulatory Schizophrenic Patients: A Controlled Study of Drug Interaction
Arch Gen Psychiatry, October 1, 1975; 32(10): 1295 - 1307.
[Abstract] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1964 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. Academy of Psychosomatic Medicine
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org